Objective: Peptide receptor radionuclide therapy (PRRT) is dependent upon binding of radiolabelled peptides to their respective receptor expressing cells. The main objective of this study was to characterize the expression of somatostatin receptor (SSTR) subtypes in non-medullary thyroid cancers in order to be able to recommend the use of PRRT as a treatment option in patients with progressive local or metastatic disease.
Design: We constructed tissue microarrays from paraffin blocks prepared from 47 cases of non-medullary thyroid carcinomas and related normal thyroid tissue. Immunohistochemical staining was performed with five different polyclonal SSTR antibodies.
Results: SSTR subtypes sst2 and sst3 were expressed in all non-medullary thyroid carcinomas, sst1 and sst5 in 75%, and sst4 in 38%. Coexpression of more than three subtypes was detected in 36 of the 47 cases. The expression of SSTR subtypes in normal thyroid tissue was low or absent.
Conclusions: Non-medullary thyroid carcinomas frequently express all SSTR subtypes. This expression provides a basis for further studies with the aim of exploring PRRT as a possible new treatment for iodine-131 refractory metastatic non-medullary thyroid carcinomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.14310/horm.2002.1357 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic treatments targeting communication between angiogenic and immune microenvironments in thyroid cancers.
Curr Opin Endocr Metab Res
December 2024
Human thyroid cancers preclinical and translational research program, Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Thyroid cancer treatment has recently been revolutionized by the introduction of specific targeted therapies (e.g. BRAF or highly selective RET inhibitors), anti-angiogenic agents (e.
View Article and Find Full Text PDFNovel truncating germline variant reinforces as a susceptibility gene for familial non-medullary thyroid cancer.
J Med Genet
September 2024
Endocrinology, ICMDM, Hospital Clinic de Barcelona, Barcelona, Spain.
Background: It has long been observed that there are families in which non-medullary thyroid cancer (NMTC) occurs, but few syndromes and genes have been described to date. Proteins in the shelterin complex have been implied in cancer. Here, we have studied shelterin genes in families affected by NMTC (FNMTC).
View Article and Find Full Text PDFDigoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma.
Eur Thyroid J
August 2024
Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands.
Objective: Patients with non-medullary thyroid carcinoma (NMTC) that are refractory to radioactive iodine (RAI) have a poor prognosis. Strategies for restoring the ability to take up iodine, so-called redifferentiation, are promising but not suitable for all patients. Preclinical studies, in human cell lines just as in a murine model, have shown that the cardiac glycoside digoxin restored RAI uptake.
View Article and Find Full Text PDF[Research progress of nonsyndromic familial non-medullary thyroid carcinoma].
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
June 2024
Department of Surgical Oncology, Affiliated Hospital of Qinghai University, Xining 810012, China.
Chromosomal localization of mutated genes in non-syndromic familial thyroid cancer.
Front Oncol
March 2024
Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Familial non-medullary thyroid carcinoma (FNMTC) is a type of thyroid cancer characterized by genetic susceptibility, representing approximately 5% of all non-medullary thyroid carcinomas. While some cases of FNMTC are associated with familial multi-organ tumor predisposition syndromes, the majority occur independently. The genetic mechanisms underlying non-syndromic FNMTC remain unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!